Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

In utero antidepressant exposure and neurodevelopment in preterm infants.

Batton B, Batton E, Weigler K, Aylward G, Batton D.

Am J Perinatol. 2013 Apr;30(4):297-301. doi: 10.1055/s-0032-1324697. Epub 2012 Aug 14.

PMID:
22893558
2.

Breastfeeding, exposure to organochlorine compounds, and neurodevelopment in infants.

Ribas-Fitó N, Cardo E, Sala M, Eulàlia de Muga M, Mazón C, Verdú A, Kogevinas M, Grimalt JO, Sunyer J.

Pediatrics. 2003 May;111(5 Pt 1):e580-5.

PMID:
12728113
3.

Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect.

Hanley GE, Brain U, Oberlander TF.

Early Hum Dev. 2013 Aug;89(8):519-24. doi: 10.1016/j.earlhumdev.2012.12.012. Epub 2013 Feb 4.

PMID:
23384962
4.

Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.

Lund N, Pedersen LH, Henriksen TB.

Arch Pediatr Adolesc Med. 2009 Oct;163(10):949-54. doi: 10.1001/archpediatrics.2009.164. Erratum in: Arch Pediatr Adolesc Med. 2009 Dec;163(12):1143.

PMID:
19805715
5.

Neonatal growth outcomes at birth and one month postpartum following in utero exposure to antidepressant medication.

Lewis AJ, Galbally M, Opie G, Buist A.

Aust N Z J Psychiatry. 2010 May;44(5):482-7. doi: 10.3109/00048670903559593.

PMID:
20397792
6.

Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.

Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC.

Psychopharmacology (Berl). 2011 Sep;217(2):211-9. doi: 10.1007/s00213-011-2270-z. Epub 2011 Apr 16.

PMID:
21499702
7.

Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose.

Roca A, Garcia-Esteve L, Imaz ML, Torres A, Hernández S, Botet F, Gelabert E, Subirà S, Plaza A, Valdés M, Martin-Santos R.

J Affect Disord. 2011 Dec;135(1-3):208-15. doi: 10.1016/j.jad.2011.07.022. Epub 2011 Sep 3.

PMID:
21890210
8.

Neurodevelopmental outcome of premature infants after antenatal phenobarbital exposure.

Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, Korones SB, Stevenson DK, Donovan EF, Stoll BJ, Fanaroff AA, Oh W, Verter J.

Am J Obstet Gynecol. 2002 Jul;187(1):171-7.

PMID:
12114906
9.

Infant neurodevelopment following in utero exposure to antidepressant medication.

Austin MP, Karatas JC, Mishra P, Christl B, Kennedy D, Oei J.

Acta Paediatr. 2013 Nov;102(11):1054-9. doi: 10.1111/apa.12379. Epub 2013 Aug 27.

PMID:
23927695
10.

Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants.

Brown MS, Eichorst D, Lala-Black B, Gonzalez R.

Pediatrics. 2009 Oct;124(4):e681-7. doi: 10.1542/peds.2008-2701. Epub 2009 Sep 28.

PMID:
19786428
11.

Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C.

Arch Gen Psychiatry. 2006 Aug;63(8):898-906.

PMID:
16894066
12.

Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta-analysis.

Eke AC, Saccone G, Berghella V.

BJOG. 2016 Nov;123(12):1900-1907. doi: 10.1111/1471-0528.14144. Epub 2016 May 30. Review.

13.

Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors.

Grzeskowiak LE, Gilbert AL, Morrison JL.

J Clin Psychopharmacol. 2012 Oct;32(5):615-21. doi: 10.1097/JCP.0b013e31826686bc.

PMID:
22926594
14.

Flash visual evoked potentials in preterm infants.

Feng JJ, Wang WP, Guo SJ, Liu ZW, Xu X.

Ophthalmology. 2013 Mar;120(3):489-94. doi: 10.1016/j.ophtha.2012.08.025. Epub 2012 Nov 20.

PMID:
23177367
15.

Poor postnatal head growth in very preterm infants is associated with impaired neurodevelopment outcome.

Neubauer V, Griesmaier E, Pehböck-Walser N, Pupp-Peglow U, Kiechl-Kohlendorfer U.

Acta Paediatr. 2013 Sep;102(9):883-8. doi: 10.1111/apa.12319. Epub 2013 Jul 10.

PMID:
23772884
16.

Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes.

El Marroun H, Jaddoe VW, Hudziak JJ, Roza SJ, Steegers EA, Hofman A, Verhulst FC, White TJ, Stricker BH, Tiemeier H.

Arch Gen Psychiatry. 2012 Jul;69(7):706-14. doi: 10.1001/archgenpsychiatry.2011.2333.

PMID:
22393202
17.

Risks associated with selective serotonin reuptake inhibitors in pregnancy.

Malm H, Klaukka T, Neuvonen PJ.

Obstet Gynecol. 2005 Dec;106(6):1289-96.

PMID:
16319254
18.

Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure.

Oberlander TF, Grunau RE, Fitzgerald C, Papsdorf M, Rurak D, Riggs W.

Pediatrics. 2005 Feb;115(2):411-25.

PMID:
15687451
19.

Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors.

Pawluski JL, Galea LA, Brain U, Papsdorf M, Oberlander TF.

Pediatrics. 2009 Oct;124(4):e662-70. doi: 10.1542/peds.2009-0442. Epub 2009 Sep 28.

PMID:
19786426
20.

Neurobehavioral assessment predicts differential outcome between VLBW and ELBW preterm infants.

Constantinou JC, Adamson-Macedo EN, Mirmiran M, Ariagno RL, Fleisher BE.

J Perinatol. 2005 Dec;25(12):788-93.

PMID:
16292337

Supplemental Content

Support Center